Last reviewed · How we verify
NCT03638271
Cardiac Magnetic Resonance in Non Ischemic Cardiomyopathy
NA trial testing Cardiac magnetic resonance imaging in Cardiac Magnetic Resonance Imaging in Non Ischemic Cardiomyopathy in 50 participants. Status unknown.
1 October 2021
Quick facts
| Lead sponsor | Reham Sameeh |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 50 |
| Start date | 1 October 2021 |
| Primary completion | 1 October 2021 |
| Estimated completion | 1 October 2021 |
Drugs / interventions tested
- Cardiac magnetic resonance imaging
Conditions studied
- Cardiac Magnetic Resonance Imaging in Non Ischemic Cardiomyopathy — all drugs for Cardiac Magnetic Resonance Imaging in Non Ischemic Cardiomyopathy →
Sponsor
Reham Sameeh
Who can join
Adults 18 to 80, any sex, with Cardiac Magnetic Resonance Imaging in Non Ischemic Cardiomyopathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cardiac magnetic resonance imaging has been established as a promising three dimensional imaging modality with the ability to assess cardiac morphology, ventricular function, perfusion, viability and imaging characteristics of the surrounding vasculature without ionizing radiation. The accurate treatment of patients with cardiac disorders has created the need for accurate and reproducible measurements of cardiac chamber volumes and function. Cardiac magnetic resonance has the ability to provide this information as well as assess edema, perfusion, viability and vascular anatomy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03638271
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cardiac magnetic resonance imaging
Trials testing the same drug.
- NCT05860504 — Acute Cardiac Dysfunction in Critical Illnes · unknown
- NCT04599439 — CMR Based Prediction of Ventricular Tachycardia Events in Healed Myocardial Infarction (DEVELOP-VT) · unknown
- NCT04886713 — Adipose Tissue Inflammation in HFpEF · unknown
- NCT07331116 — Echocardiography Findings in Patients With Myocardial Fibrosis and Severe Aortic Stenosis · completed
- NCT03516578 — CMR for Prognosis Assessment in NSTEMI · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03638271 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Reham Sameeh
- Last refreshed: 29 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03638271.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing